All

Results: 38377-38388 of 47389

PR Newswire associated0

Epitomee® Announces Successful Completion of Pivotal Clinical Trial for Innovative Weight Loss Capsule

GTT Expands Its SASE Portfolio With Fortinet to Offer Enterprises a Robust Suite of Security Solutions Uniquely Enabled by GTT’s Global Tier 1 IP Backbone

U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

KBI Biopharma, Inc. and Argonaut Manufacturing Services, Inc. Forge Strategic Alliance to Support Global Biopharmaceutical Companies with Integrated Drug Substance and Drug Product Solutions

KAYAK reveals when to book flights for popular summer holidays

Single Use Support continues to grow, expanding its team by 40%

PR Newswire associated0

Innovative Data Center Solutions Provider Inova Announces Its Launch

On January 11th, trailblazing medical technology company Xenco Medical unveiled its convergent technology bridging Digital Health and Biomaterials by showcasing its TrabeculeX Continuum™ at the 2024 Consumer Electronics Show in Las Vegas, Nevada. Comprising the TrabeculeX Bioactive Matrix™ and the TrabeculeX Recovery App™, the TrabeculeX Continuum is the first technology-enabled bridge between orthobiologics and digital health, unifying a patient’s biomaterial implantation and postoperative journey. (Graphic: Business Wire)

Xenco Medical Unveils the TrabeculeX Continuum, a Breakthrough Convergence of Digital Health and Biomaterials, at CES 2024 in Las Vegas, the World’s Largest Technology Conference

Morgan Stanley Fourth Quarter and Full Year 2023 Earnings Results

LumiThera Announces Initiation of EUROLIGHT Registry Study to Evaluate Long-term Benefits of Photobiomodulation (PBM) Treatment using the Valeda® Light Delivery System in Patients with Dry Age-Related Macular Degeneration (AMD)

Envision Pharma Group Appoints Life Sciences Industry Veteran Alice Choi as President, Integrated Medical Capabilities and Solutions (IMC)

Aviceda Therapeutics Announces Topline Data from Part 1 of the Phase 2/3 SIGLEC Clinical Trial for AVD-104, Demonstrating Positive Safety and Early Clinical Efficacy in Patients with Geographic Atrophy